HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Clinical trials, ‘a lot more study’ needed to confirm statins’ effects on cancer outcomes
• Abstracts highlight importance of identifying, managing germline mutations in patients with somatic genomic testing of cancer Charis Eng, MD, PhD
• Hematology, oncology communities react to ACA decision
• Statins may be more than a smoking gun, but level one data still lacking Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Iressa for EGFR-mutated NSCLC
• FDA approves cangrelor for reduction of thrombotic events in patients with CAD needing PCI
• FDA grants orphan drug designation to ATX-F8-117 for hemophilia A
• FDA grants orphan drug designation to BLZ-100 for brain cancer
• ODAC discusses necitumumab for squamous NSCLC but takes no action
• Thyroid cysts not always benign Stephanie L. Lee, MD, PhD, ECNU
• Gardasil 9 HPV vaccine also safe, effective in younger boys, girls
• ADT may impair cognitive function in patients with prostate cancer
• Bevacizumab combination safe, effective for endometrial cancer
• Gene therapy shows promise in Wiskott-Aldrich syndrome
• Hydroxyurea may be underused for patients with sickle cell anemia
• Late mortality, morbidity rates increase among survivors of adult Hodgkin's lymphoma
• Lenvatinib shows promise for radioiodine-refractory, differentiated thyroid cancer
• Leukemia patients at greater risk for C. difficile
• Men with AR-V7 variant may benefit from taxanes for advanced prostate cancer
• MRD monitoring may guide risk-based therapy in pediatric ALL
• Obesity increases prostate cancer risk in black men
• Older patients with AML underutilize end-of-life care
• Pacritinib demonstrates safety, efficacy for patients with myelofibrosis
• Pediatric cancer treatments increase risk for obesity in adulthood
• Presence of unexpected uterine sarcoma during myomectomy increases with age
• Pulmonary defects common among childhood cancer survivors
• Researchers call for ban on tobacco sales by 2040
• Researchers identify risks for recurrence, mortality based on lung cancer stage
• Rociletinib, AZD9291 active in EGFR inhibitor-resistant NSCLC
• ROS1 rearrangements can be detected in circulating tumor cells of NSCLC
• Salvage therapies benefit patients with CLL after allogeneic SCT failure
• Value of PFS as surrogate in NSCLC varies considerably
• Cancer center director appointed association president
• City of Hope names director for gene therapy center
• Conquer Cancer Foundation honors community practices
• ESMO announces 2018-2019 president
• Top Takeaways from ASCO: Melanoma
• Comprehensive genetic profiling reveals promising data on hereditary cancers
• ERY001 yields positive outcomes for treatment of relapsed ALL
• HBV may lead to more aggressive form of HCC than HCV
• Low BMI associated with shorter OS in mCRC patients
• Proton beam therapy improves OS in patients with ICC
• Second-line cetuximab plus FOLFOX extends PFS in wild-type metastatic colorectal cancer
• Study confirms regorafenib benefit for previously treated metastatic colorectal cancer
• Top Takeaways from ASCO: Advanced squamous cell carcinoma of the head and neck
• Top Takeaways from ASCO: Breast Cancer
• Top Takeaways from ASCO: HER-2–positive breast cancer
• Top Takeaways from ASCO: Neuro-oncology
• Top Takeaways from ASCO: Prostate Cancer
• Top Takeaways from ASCO: Urothelial Cancer
• A look at coagulation assays for target-specific oral anticoagulants Shreya Patel, PharmD, BCPS; Eyerusalem Befkadu, PharmD candidate